Cepheid (Nasdaq: CPHD), based in Sunnyvale, California, is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the ...

SUNNYVALE, Calif., Feb. 10, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that Warren Kocmond, formerly Executive Vice President and Chief Operating Officer, has been promoted to the ...

SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert ® HIV-1 Viral Load XC, a next-generation extended-coverage (XC ...

SUNNYVALE, Calif., Sept. 29, 2020 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress ...

SUNNYVALE, Calif., April 3, 2024 /PRNewswire/ -- Cepheid today announced that Xpert® HIV-1 Qual XC has been awarded World Health Organization (WHO) prequalification. Inclusion on the prequalification ...

LONDON, Nov 15 (Reuters) - Global health advocates have written to the makers of a key mpox diagnostic test to call for its price to be cut from around $20 per test to $5, to help tackle low testing ...

Cepheid's performance in the first quarter was driven by robust growth in clinical product sales resulting from test utilization in the emerging HAI test market for Xpert MRSA, continued adoption of ...

For much of last year, the coronavirus crept, undetected, across eastern Democratic Republic of Congo. Test samples had to be sent more than 1,500 kilometres from remote hospitals to the capital ...